// App-Quantinova.ai

16383 : Inhibition of Egfr Signalling Promotes Maladaptive Cardiac Remodelling in Hypertensive Heart Disease

Researchers

Presenter

  • Susanna Cooper

Principal Investigators

  • Zoe Haines

  • Viridiana Alcantara Alonso

  • Joshua J Cull

  • Feroz Ahmad

  • Hajed O Alharbi

  • Stephen Fuller

  • Peter Sugden

  • Angela Clerk

  • Daniel N Meijles

Medical Centers

  • St George's, University of London, London, United Kingdom

  • St George's, Univ of London, London

  • University of Reading, Reading, United Kingdom

  • Sch of Biological Sciences, Univ of Reading, Univ of Reading, United Kingdom

  • Univ of Reading, Reading

  • UNIVERSITY OF READING, Reading

  • St George's, University of London, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hypertensive heart disease

  • Hypertrophic cardiomyopathy

  • Hypertension

  • Solid malignancies

Biomarkers

  • Mitogen-activated protein kinase 3

Drug/Treatment

  • Angiotensin II

  • Afatinib

Outcome

  • N/A

Study Design

  • Cross-Sectional

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved